What happened with STOK today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Stoke Therapeutics is a clinical-stage biotechnology company developing medicines for genetic diseases in which the body makes too little of a needed protein. Its TANGO approach uses RNA-based drugs to increase production of that protein. Its main focus is zorevunersen for Dravet syndrome; it also develops STK-002 for ADOA.
Biogen supplies most of Stoke’s revenue through their collaboration on zorevunersen and related drugs. Biogen paid an upfront license fee and pays for development activities. Stoke leads global development and bears most of the shared development costs, while Biogen holds exclusive rights outside the United States, Canada and Mexico. Stoke can receive further payments when specified development or commercial milestones are met, plus royalties on future sales in Biogen’s territory. A smaller collaboration with Acadia Pharmaceuticals covers potential medicines for SYNGAP1 syndrome.
Stoke has no approved products and earns no revenue from selling drugs. Its business therefore depends on these collaborations continuing and its candidates completing clinical development and obtaining regulatory approval. Its foundational TANGO technology is licensed from the University of Southampton; retaining those rights requires Stoke to meet the license’s obligations.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Stoke’s prospects hinge chiefly on zorevunersen’s clinical success in Dravet syndrome, where privately held Encoded Therapeutics is also testing a treatment that regulates genes to address the underlying cause.
Biogen helps fund Stoke’s SCN1A medicines, including zorevunersen, covering 30% of agreed development costs in exchange for exclusive rights outside the United States, Canada and Mexico. Development milestones and future sales in those markets matter to Stoke’s potential milestone payments and sales royalties; no milestones had been met by December 31, 2025.
Acadia Pharmaceuticals licenses Stoke’s SYNGAP1 medicines, sharing worldwide development costs and future profits equally, so progress in this program matters to both companies. Acadia ended its MECP2 and undisclosed neurodevelopmental programs with Stoke in September 2025; Stoke’s Acadia collaboration revenue fell from $36.6 million in 2024 to $16.1 million in 2025.
Ionis Pharmaceuticals competes with Stoke in developing Dravet syndrome treatments, and both use short strands called oligonucleotides to change gene expression. Ionis’s Dravet development progress is the relevant news for Stoke, rather than sales across Ionis’s existing medicines.
Praxis Precision Medicines competes with Stoke in epilepsy and neurodevelopmental drug development, including candidates targeting SYNGAP1. Praxis has no product-sales revenue yet, so progress in its SYNGAP1 candidates is the clearest news to watch for competition with Stoke’s program.
Jazz Pharmaceuticals already sells Epidiolex to treat Dravet seizures, while Stoke is developing a treatment intended to address the syndrome’s underlying genetic cause. Epidiolex treats the same patient group, but its sales also include Lennox-Gastaut syndrome and tuberous sclerosis complex, so they are not a pure measure of the Dravet market.
CAMP4 Therapeutics directly competes with Stoke in developing SYNGAP1 candidates; both design short strands called antisense oligonucleotides to increase gene expression. CAMP4 has no product-sales revenue, making progress in its SYNGAP1 candidates—not current drug sales—the relevant competitive signal for Stoke.
Xenon Pharmaceuticals develops epilepsy medicines, and Stoke names it among developers of Dravet treatments competing with its lead program. Xenon’s lead drug azetukalner is in Phase 3 epilepsy trials, not already on sale; those results are worth watching without treating them as Dravet-specific evidence.
Harmony Biosciences and Stoke both develop Dravet syndrome treatments, placing their pipelines in the same rare-epilepsy market. For Stoke, Harmony’s Dravet development news is more relevant than its current WAKIX sales to specialty distributors.
Bright Minds Biosciences is developing BMB-101 for developmental and epileptic encephalopathies, overlapping the Dravet treatment market targeted by Stoke’s lead therapy. Its ongoing Phase 2 results in these patients are the news to watch; Bright Minds has no commercial production yet.
Biogen Inc. earningsBIIB
Biogen’s report will show how its business is doing as it funds 30% of agreed SCN1A development costs and holds rights to develop and sell those medicines outside North America.
Read Biogen’s business results alongside any disclosed progress or spending on the collaboration. A steady business and continued work would support Biogen’s ability to pay its agreed 30% share, while Stoke still bears 70% of budgeted development costs. If Biogen is under pressure or the program slows, Stoke’s larger cost share matters more; milestones and sales royalties remain contingent, not current income. The report can inform confidence in the partnership, not prove the medicine works or will sell.
Fed Interest Rate Decision
Stoke’s Fed interest-rate decision matters because it can change what the company earns on its cash and investments, which totaled $390.9 million at year-end 2025, and its $13.8 million of net interest income in 2025.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher rates could lift returns on rate-sensitive cash investments and add to Stoke’s interest income, while higher borrowing costs could make future financing more expensive if the company needs to raise capital.
If it comes in below expectations
Lower rates could reduce returns on rate-sensitive cash investments and Stoke’s interest income, while cheaper borrowing could ease the cost of future financing if the company needs it.
Stoke Therapeutics, Inc. earningsThis company
Stoke Therapeutics has no approved products, so this report will show how collaboration revenue changes and how research spending uses cash as it develops medicines.
Read collaboration revenue alongside research spending and operating cash flow. Revenue can be recognized as Stoke fulfills contract obligations; it is not product sales. Higher collaboration revenue with continued research spending would show partner payments supporting active programs. If revenue falls while cash use rises, Stoke is still funding development but collaboration income is providing less support. The key is whether contract income is keeping pace with the cash needed to advance its medicines.
